Cellbion

At a glance

Cellbion filed 23 disclosures in the last 12 months, including 2 issuance and 1 insider. The most recent key filing was on May 15.

Revenue for 2025 was ₩1.9B, down 15.1% on 2024. It made an operating loss of ₩8.2B. Debt was 54% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩1.1B and operating loss of ₩5.1B.

The 2025 annual report lists 56 employees with an average tenure of 2.9 years and average pay of ₩50.8M, #1421 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩86.8M each on average. It paid no cash dividend for 2025. 김권 and related parties held 36.41% at year end.

From the 2025 annual report

Staff: 56 (27 men, 29 women), of whom 1 on fixed-term contracts. Total pay for the year: ₩2.8B. Directors and auditors: 4, paid ₩347.2M in total.

No cash dividend was paid for 2025.

Largest shareholder

김권 holds 30.23%; with 5 related parties the group holds 36.41% of common shares at year end (from 36.50% at the start of the year).

Auditor: 정동회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary